LBRX
LB Pharmaceuticals Inc Common Stock·Healthcare
25.43
4.478%(+1.09)
Close PriceLast Updated: — ET
52W L: $13.3652W H: $27.55
LBRX NEWS
globenewswire.com
4d ago
LB Pharmaceuticals Announces Presentation at 25th Annual Needham Virtual Healthcare Conference
NEW YORK, April 09, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a late-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, adjunctive major depressive disorder (MDD) and other neuropsychiatric diseases, today announced that Heather Turner, Chief Executive Officer, will present at the 25th Annual Needham Virtual Healthcare Conference on Thursday, April 16, 2026, at 11:45 a.m. ET. A live webcast of the presentation will be available on the “Investors” page under the “Events” section of the Company's website at https://ir.lbpharma.us/investors/events/, where a replay of the webcast will be archived.
globenewswire.com
Mar 27
LB Pharmaceuticals Presents New Analysis from the Phase 2 NOVA-1 Trial Highlighting LB-102's Potential Impact on Cognitive Performance at the 2026 Annual Congress of the Schizophrenia International Research Society (SIRS)
Multiple SIRS presentations underscore the potential of LB-102 to address positive, negative, and cognitive symptom domains of schizophrenia Multiple SIRS presentations underscore the potential of LB-102 to address positive, negative, and cognitive symptom domains of schizophrenia
globenewswire.com
Mar 26
LB Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Reported positive results from potentially registrational Phase 2 trial ofLB-102 in schizophrenia Advanced LB-102 into late-stage development in multiple indications with initiation ofa pivotal Phase 3 NOVA-2 trial in schizophrenia, and Phase 2 ILLUMINATE-1 trialin bipolar depression Announced pipeline expansion with plans to initiate a Phase 2 trial of LB-102 for theadjunctive treatment of major depressive disorder (MDD) in early 2027 Cash, cash equivalents, and investments of $295.2 million as of December 31, 2025, and proceeds from recent $100 million private placement, expected to provide cash runway into Q2 2029 NEW YORK, March 26, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a late-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, adjunctive treatment of MDD, and other neuropsychiatric diseases, today announced financial results for the fourth quarter and full year ended on December 31, 2025 and provided a corporate update. “2025 was a transformative year for LB.
globenewswire.com
Mar 25
LB Pharmaceuticals Initiates Pivotal Phase 3 Trial (NOVA-2) for LB-102 in Patients with Schizophrenia
LB-102 has potential to be the first benzamide approved for schizophrenia in the U.S. NOVA-2 trial to enroll approximately 460 patients Primary endpoint to evaluate change in PANSS total score at week 6; secondary endpoints to include evaluations of negative symptoms and cognitive performance as well as safety and tolerability Topline data expected in 2H 2027 NEW YORK, March 25, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a late-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, adjunctive major depressive disorder (MDD), and other neuropsychiatric diseases, today announced the initiation of its pivotal Phase 3 trial (NOVA-2) evaluating the efficacy and safety of LB-102 as a treatment for schizophrenia. LB-102, a novel, once-daily, oral investigational small molecule, is a selective antagonist of D2, D3, and 5HT-7 receptors that is being advanced as a potential first benzamide in the U.S. for the treatment of neuropsychiatric disorders.
defenseworld.net
Mar 22
LB Pharmaceuticals CEO Maps LB-102 Milestones, Says Pipeline Fully Funded Into Q2 2029
LB Pharmaceuticals (NASDAQ: LBRX) CEO Heather Turner told investors the company is positioned for a series of "clinically meaningful value creating catalysts" following its most recent financing, with multiple late-stage readouts planned for its lead candidate LB-102 across several psychiatric indications. In a discussion moderated as a conversational company update, Turner emphasized that LB-102 is intended
defenseworld.net
Mar 15
LB Pharmaceuticals (NASDAQ:LBRX) Sets New 1-Year High – Here’s What Happened
LB Pharmaceuticals Inc (NASDAQ: LBRX - Get Free Report)'s stock price hit a new 52-week high during trading on Friday. The stock traded as high as $26.26 and last traded at $26.2950, with a volume of 47974 shares. The stock had previously closed at $24.94. Analyst Upgrades and Downgrades A number of equities analysts have
